Literature DB >> 16132110

Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.

Liang-Chen Chang1, Chi-Hui Huang, Chi-Hung Cheng, Bor-Huah Chen, Hong-Chen Chen.   

Abstract

Upon cell adhesion to extracellular matrix proteins, focal adhesion kinase (FAK) rapidly undergoes autophosphorylation on its Tyr-397 which consequently serves as a binding site for the Src homology 2 domains of the Src family protein kinases and several other intracellular signaling molecules. In this study, we have attempted to examine the effect of the FAK Y397F mutant on v-Src-stimulated cell transformation by establishing an inducible expression of the Y397F mutant in v-Src-transformed FAK-null (FAK(-/-)) mouse embryo fibroblasts. We found that the FAK Y397F mutant had both positive and negative effects on v-Src-stimulated cell transformation; it promoted v-Src-stimulated invasion, but on the other hand it inhibited the v-Src-stimulated anchorage-independent cell growth in vitro and tumor formation in vivo . The positive effect of the Y397F mutant on v-Src-stimulated invasion was correlated with an increased expression of matrix metalloproteinase-2, both of which were inhibited by the specific phosphatidylinositol 3-kinase inhibitor wortmannin or a dominant negative mutant of AKT, suggesting a critical role for the phosphatidylinositol 3-kinase/AKT pathway in both events. However, the expression of the Y397F mutant rendered v-Src-transformed FAK(-/-) cells susceptible to anoikis, correlated with suppression on v-Src-stimulated activation of ERK and AKT. In addition, under anoikis stress, the induction of the Y397F mutant in v-Src-transformed FAK(-/-) cells selectively led to a decrease in the level of p130(Cas), but not other focal adhesion proteins such as talin, vinculin, and paxillin. These results suggest that FAK may increase the susceptibility of v-Src-transformed cells to anoikis by modulating the level of p130(Cas).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16132110     DOI: 10.1007/s11373-005-7212-5

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  6 in total

Review 1.  Significance of talin in cancer progression and metastasis.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

2.  Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance.

Authors:  Shinichi Sakamoto; Richard O McCann; Rajiv Dhir; Natasha Kyprianou
Journal:  Cancer Res       Date:  2010-02-16       Impact factor: 12.701

3.  Global Proteomics Analysis of Bone Marrow: Establishing Talin-1 and Centrosomal Protein of 55 kDa as Potential Molecular Signatures for Myelodysplastic Syndromes.

Authors:  Arlindo A Moura; Maria Julia B Bezerra; Aline M A Martins; Daniela P Borges; Roberta T G Oliveira; Raphaela M Oliveira; Kaio M Farias; Arabela G Viana; Guilherme G C Carvalho; Carlos R K Paier; Marcelo V Sousa; Wagner Fontes; Carlos A O Ricart; Maria Elisabete A Moraes; Silvia M M Magalhães; Cristiana L M Furtado; Manoel O Moraes-Filho; Claudia Pessoa; Ronald F Pinheiro
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

4.  FAK is required for the assembly of podosome rosettes.

Authors:  Yi-Ru Pan; Chien-Lin Chen; Hong-Chen Chen
Journal:  J Cell Biol       Date:  2011-10-03       Impact factor: 10.539

5.  Modulation of Corneal FAK/PI3K/Akt Signaling Expression and of Metalloproteinase-2 and Metalloproteinase-9 during the Development of Herpes Simplex Keratitis.

Authors:  Lan Ke; Yanning Yang; Jing Wei Li; Bo Wang; Yujing Wang; Wanju Yang; Jiangbo Yan
Journal:  Biomed Res Int       Date:  2019-04-02       Impact factor: 3.411

6.  Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion.

Authors:  Sanjay Sachdev; Yahao Bu; Irwin H Gelman
Journal:  BMC Cancer       Date:  2009-01-12       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.